PCI Pharma Services Expands UK Manufacturing Facility


CDMO’s new project focuses on addressing needs in oncology sector

PCI Pharma Services, a contract development and manufacturing organization (CDMO) and biopharma global outsourcing services provider, is expanding its facility in Tredegar, Wales, UK, which is the center that handles targeted oncology therapies.

“We’re excited to announce the latest expansion in Tredegar that will address the growing and urgent need for specialty global manufacturing services within the oncology arena,” says Salim Haffar, CEO of PCI Pharma Services. “As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale.”

The expansion includes two new facilities soley for the manufacturing and packaging of solid oral-dose tablets and capsules. Along its first contained manufacturing building (CMF1), the new CMF2 is expected to double large-scale processing capacity, including dispensing and fluid bed granulation of high-potency solid-dose products at the commercial scale. There is also a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites. The primary and secondary packaging lines provide a fully integrated process, in order to deliver end-to-end services.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.